AXL and hepatocellular carcinoma: Although AXL has been implicated in conferring drug resistance and mediating immunomodulatory functions, the therapeutic potential of AXL inhibition in potentiating ICI-based therapy in drug-resistant cancers, for example, HCC, has not been studied.